BRIEF—Novo Nordisk to expand R&D presence in greater Boston, USA, area

Danish diabetes care giant Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston, USA, metro area, creating one of its largest R&D hubs outside of Denmark.

This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s USA-based research and development activities.

The company says it anticipates adding more than 200 new jobs in the Boston area in 2023.

Of these new positions, more than 150 will be lab-based and clinical development personnel in Lexington and Watertown and involved in data science, biology or chemistry research, and ribonucleic acid interference (RNAi) research and clinical development.

In 2022, Novo Nordisk began to convert a 100,000 square foot space, which includes a state-of-the art new lab, adjacent to its existing facilities in Lexington.

This facility will house its RNAi research and development and oral formulation units.